Format

Send to

Choose Destination
Eur J Surg Oncol. 2015 Feb;41(2):228-35. doi: 10.1016/j.ejso.2014.11.037. Epub 2014 Nov 20.

Expression and clinical value of peroxiredoxin-1 in patients with pancreatic cancer.

Author information

1
Department of General Surgery, Anhui Provincial Hospital Affiliated with Anhui Medical University, No. 17 Lujiang Road, Hefei 230001, Anhui Province, People's Republic of China; Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, No. 17 Lujiang Road, Hefei 230001, Anhui Province, People's Republic of China.
2
Department of General Surgery, Anhui Provincial Hospital Affiliated with Anhui Medical University, No. 17 Lujiang Road, Hefei 230001, Anhui Province, People's Republic of China; Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, No. 17 Lujiang Road, Hefei 230001, Anhui Province, People's Republic of China. Electronic address: jackyzhai123@163.com.
3
Department of General Surgery, Anhui Provincial Hospital Affiliated with Anhui Medical University, No. 17 Lujiang Road, Hefei 230001, Anhui Province, People's Republic of China; Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, No. 17 Lujiang Road, Hefei 230001, Anhui Province, People's Republic of China. Electronic address: tzg567@163.com.

Abstract

BACKGROUND:

Peroxiredoxin-1 (Prx-1) is an important protector for redox damage and its abnormal expression is continually reported in various tumors. This study aims to investigate the expression status of Prx-1 and evaluate its clinical value in pancreatic cancer.

METHODOLOGY:

Immunohistochemistry was used to detect Prx-1 expression in pancreatic cancer tissues and para-cancerous tissues. Enzyme-linked immunosorbent assay (ELISA) method was applied to detect the serum Prx-1 levels.

RESULTS:

The immunohistochemical results indicated that positive rate of Prx-1 was (p < 0.05) higher in pancreatic cancer tissues (74.4%) than in para-cancerous tissues (37.2%). Prx-1 expression was positively correlated with vascular endothelial growth factor (VEGF) and microvessel density (MVD) in cancer tissues. The ELISA results showed that patients with pancreatic cancer had a higher serum Prx-1 level than healthy subjects (31.2 ± 13.5 vs. 13.2 ± 11.9 ng/ml, p < 0.001). Prx-1 expression was correlated with aggressive clinicopathological parameter. The combination of serum Prx-1 and CA19-9, the area under the curve (AUC) was significantly higher than Prx-1 separate. Positive Prx-1 expression was correlated with disappointing overall survival (OS) (p = 0.002) and disease-free survival (DFS) (p < 0.001). Multivariate analysis showed that Prx-1 staining as an independent biomarker of poor OS (p = 0.035) and DFS (p < 0.001).

CONCLUSION:

These findings suggest that the levels of Prx-1 expression are significantly increased in pancreatic cancer. The up-regulated Prx-1 is closely related to tumor angiogenesis and acts as a promising tumor marker for diagnosis and prognosis of pancreatic cancer.

KEYWORDS:

Diagnosis; Maker; Pancreatic cancer; Peroxiredoxin-1; Prognosis; Prx-1

PMID:
25434328
DOI:
10.1016/j.ejso.2014.11.037
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center